Dear Sir,
A recent and very interesting study by Yang et al., published in Carcinogenesis, showed that two single-nucleotide polymorphisms (SNPs), the rs2056116 and rs9572903, located within ultraconserved elements, were associated with breast cancer (BC) risk, by comparing 1214 German index patients negative for mutations in BRCA1 and BRCA2 genes and 2084 German female blood donors (1) . While rs9573903 showed borderline association with BC risk, the association of rs2056116 was stronger. In particular, the association of rs2056116 was accounted by cases defined as high risk because (i) from families with one or more cases of BC and at least one case of ovarian cancer or (ii) from families with two or more cases of BC including at least two cases with onset under the age of 50 (1, 2) In order to verify the reliability of these results in an independently ascertained yet similar series of cases and controls, we genotyped the SNPs rs2056116 and rs9573903 in 737 Italian female familial BC cases negative for mutations in BRCA1 and BRCA2 genes and 1245 Italian female blood donors. The cases were originally ascertained through the genetic counseling activity of the Unit of Medical Genetics at Fondazione IRCCS Istituto Nazionale Tumori (INT) and the Division of Cancer Prevention and Genetics at Istituto Oncologico (Table I) . Moreover, we subdivided the cases in high and low risk applying the same criteria as in the study by Yang et al.
(1) and cases and controls in two groups according to the threshold age of 50 years (Table I) . None of the performed analyses resulted statistically significant. We pursued the analysis by studying the effect of rs2056116 and rs9572903 SNPs in the 109 cases affected with bilateral BC compared with all 1245 controls (Table II) . In this analysis, we observed a marginally significant protective effect limitedly to the heterozygous genotype of rs2056116 ([AG] versus [AA]: OR 5 0.62, 95% CI 0.40-0.96, P 5 0.031). As this analysis was based on a small number of cases, this observation should be taken with caution and needs to be confirmed in larger sample sets.
Altogether, our results indicated that the genotype frequencies of SNPs rs2056116 and rs9572903 were not different in cases versus controls, thus failing to support the association of rs2056116 with BC risk. In addition, no association was found when considering subgroups according to age or cancer risk based on family history. Thus, our results failed to confirm those by Yang et al. (1) . Population-specific factors may explain this discrepancy. In fact, rs2056116 might have a different effect in the two populations analyzed due to putative different genetic background; otherwise, rs2056116 can be in linkage disequilibrium with another causative variant present in Germans and not in Italians. However, we believe that, most probably, the difference between our results and those by Yang et al. (1) is explained by statistical fluctuations that are expected when a relatively small number of samples are tested. Therefore, only large analyses would prove whether or not rs2056116 is associated with increased BC risk. In conclusion, our results do not support the association between rs2056116 or rs9572903 SNPs and BC risk not attributable to mutations in BRCA genes. Letter to the editor
